Table 2.
Cox regression analysis for progression-free survival
| N | n | Progression-free survival | ||||
|---|---|---|---|---|---|---|
| Age-adjusted HR [95% CI] | p value | multivariate HRa [95% CI] | p value | |||
| Baseline Tie1 | ||||||
| Low | 27 | 16 | 1 | 1 | ||
| High | 26 | 15 | 2.13 [1.02–4.46] | 0.043 | 3.78 [1.57–9.09] | 0.003 |
| Baseline Ang2 | ||||||
| Low | 27 | 14 | 1 | 1 | ||
| High | 26 | 17 | 1.21 [0.59–2.47] | 0.597 | 1.22 [0.54–2.77] | 0.620 |
| Combined analysis | ||||||
| Tie1 and Ang2 low | 18 | 9 | 1 | 1 | ||
| Tie1 low, Ang2 high | 9 | 7 | 1.27 [0.47–3.43] | 0.632 | 1.16 [0.39–3.39] | 0.783 |
| Tie1 high, Ang2 low | 9 | 5 | 3.86 [1.18–12.57] | 0.025 | 4.45 [1.25–15.79] | 0.021 |
| Tie1 and Ang2 high | 17 | 10 | 2.02 [0.80–5.07] | 0.133 | 3.88 [1.25–12.06] | 0.019 |
Abbreviations: N number of patients, n number of events, HR hazard ratio, CI confidence interval. Statistically significant results are highlighted in bold
aHazard ratio adjusted by age, menopausal status, hormone receptor status, presence of visceral metastasis, number of metastatic lesions and extent of the disease